Efficacy of Patient Management for Lymphoma Diagnosed at Nimes University Hospital From 1999 to 2018. DVR-Lym-Nim

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age15+
SponsorCentre Hospitalier Universitaire de Nīmes

About this trial

Observation of a cohort of 400 patients with different types of lymphomas.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patients over the age of 15 years and 3 months, diagnosed with lymphoma at Nîmes University Hospital as from 1999 onwards and for whom diagnostic tumor material is available.

Disqualifiers

Patients aged 18 or over who have expressed their desire not to take part in the study.

Patients under the age of 18 whose legal representatives have expressed their desire for the child not to take part in the study.

Patients under legal guardianship.

Trial population

The population consists of patients with lymphomas (Malignant Non-Hodgkinien and Hodgkin Lymphomas) diagnosed at Nîmes University Hospital from 1999 onwards and for whom the frozen biological samples are available. Since 2005, all patients have been registered in the Tumototek software program. Those diagnosed before this date can be found in the hospital's anatomopathological laboratory registers.

Trial design

Design model

Cohort

Time perspective

Retrospective

Treatments tested in this trial

Not listed

Trial groups

No trial groups listed

Trial outcomes

Primary outcomes

1

Overall survival rate among patients with Hodgkin Lymphomas

The number of months during which the patient has survived since inclusion will be noted. If the patient has died, the date of death recorded in the hospital file or from the INSERM CépiDC register will be noted.

Time frame
2 years after inclusion
2

Overall survival rate among patients with Mantle-cell Lymphomas

The number of months during which the patient has survived since inclusion will be noted.If the patient has died, the date of death recorded in the hospital file or from the INSERM CépiDC register will be noted.

Time frame
2 years after inclusion
3

Overall survival rate among patients with Primitive Cerebral Lymphomas

The number of months during which the patient has survived since inclusion will be noted. If the patient has died, the date of death recorded in the hospital file or from the INSERM CépiDC register will be noted.

Time frame
2 years after inclusion
4

Overall survival rate among patients with Follicular Lymphomas

The number of months during which the patient has survived since inclusion will be noted. If the patient has died, the date of death recorded in the hospital file or from the INSERM CépiDC register will be noted.

Time frame
2 years after inclusion

Secondary outcomes

1

Differences between management of patients with Hodgkin Lymphomas actually observed and data described in the literature.

The actual management of these patients will be compared with the data in the literature and any differences will be noted.

Time frame
2 years after inclusion
2

Differences between management of patients with Mantle-cell Lymphomas and data described in the literature.

The actual management of these patients will be compared with the data in the literature and any differences will be noted.

Time frame
2 years after inclusion
3

Differences between management of patients with Primitive Cerebral Lymphomas and data described in the literature.

The actual management of these patients will be compared with the data in the literature and any differences will be noted.

Time frame
2 years after inclusion
4

Differences between management of patients with Follicular Lymphomas and data described in the literature.

The actual management of these patients will be compared with the data in the literature and any differences will be noted.

Time frame
2 years after inclusion

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.